Abstract
Prolonged continuous infusion of low-dose rIL-2
Highlights
We would like to comment that these observations might be influenced by the time points of analysis
In a longitudinal study during low-dose subcutaneous IL-2 therapy we demonstrated that IL-2 therapy does induce T-cell activation, as assessed by the increased expression of HLA-DR, during the first week of therapy, followed by a decrease in the number of T cells expressing the activated phenotype (Janssen et al, 1993)
It has been demonstrated that T cells sampled during IL-2 therapy become unresponsive to in vitro stimulation with CD3 monoclonal antibody (MAb) (Weil-Hillman et al, 1991; Janssen et al, 1993)
Summary
We would like to comment that these observations might be influenced by the time points of analysis. In a longitudinal study during low-dose subcutaneous IL-2 therapy we demonstrated that IL-2 therapy does induce T-cell activation, as assessed by the increased expression of HLA-DR, during the first week of therapy, followed by a decrease in the number of T cells expressing the activated phenotype (Janssen et al, 1993). Other investigators have reported T-cell activation during low-dose continuous intravenous infusion (Yoshino et al, 1991).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
